- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
EBITDA of Aurobindo Pharma Limited in India 2012-2018
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
EBITDA of Aurobindo Pharma Limited in India 2012-2018
EBITDA of Aurobindo Pharma Limited in India from FY 2013 to 2018 (in billion Indian rupees)
This statistic shows the earnings before interest, tax, depreciation and amortization (EBITDA) value of Aurobindo Pharma Limited in India from financial year 2013 to financial year 2018. As seen, in fiscal year 2018, Aurobindo Pharma's EBITDA value was around 38 billion Indian rupees.
EBITDA of Aurobindo Pharma Limited in India from FY 2013 to 2018 (in billion Indian rupees)
| EBITDA in billion Indian rupees | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| EBITDA in billion Indian rupees | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
© Statista 2019
About this statistic
Show source
Please be patient - this may take a moment
Description
Source
More information
- Show sources information
- Show publisher information
- Release date
- April 2018
- Region
- India
- Survey time period
- FY 2013 to FY 2018
- Supplementary notes
-
EBITDA refers to earnings before interest, tax, depreciation and amortization.
*Includes higher sales from limited competition product.
One Indian rupee is equal to 0.013 euros and 0.014 U.S. dollars (as of April 2019).
India's fiscal year starts in April and ends in March. For example, FY 2018 started in April 2017 and ended in March 2018.
Source
- Show sources information
- Show publisher information
- Release date
- April 2018
More information
- Region
- India
- Survey time period
- FY 2013 to FY 2018
- Supplementary notes
-
EBITDA refers to earnings before interest, tax, depreciation and amortization.
*Includes higher sales from limited competition product.
One Indian rupee is equal to 0.013 euros and 0.014 U.S. dollars (as of April 2019).
India's fiscal year starts in April and ends in March. For example, FY 2018 started in April 2017 and ended in March 2018.
Other statistics on the topic
+Pharmaceutical Products & Market
Animal health leading companies by revenue 2018
+Pharmaceutical Products & Market
Global animal health market 2002-2018
Pharmaceutical Products & Market
Distribution of global animal health care market by species 2018
+Pharmaceutical Products & Market
Top global mergers and acquisitions in animal health 2014-2018, by enterprise value
You only have access to basic statistics.
This statistic is not included in your account!
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate solution including all features.
Prices do not include sales tax.
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation
- Global positioning
- Global animal health market size from 2002 to 2018 (in billion U.S. dollars)Global animal health market 2002-2018
- Global animal health yearly market revenue growth from 2013 to 2018Animal health global market revenue growth 2013-2018
- Leading animal health companies in 2018, based on revenue (in billion U.S. dollars)Animal health leading companies by revenue 2018
- Distribution of global animal health care market volume in 2018, by speciesDistribution of global animal health care market by species 2018
- Top animal health mergers and acquisitions worldwide between 2014 and 2018, by enterprise value (in million U.S. dollars)Top global mergers and acquisitions in animal health 2014-2018, by enterprise value
- Revenue figures
- Zoetis global revenue from 2014 to 2018 (in million U.S. dollars)Zoetis revenue 2014-2018
- Zoetis' global revenue in 2018, by country (in million U.S. dollars)Zoetis revenue in 2018, by country
- Zoetis' revenue from 2016 to 2018, by animal type (in million U.S. dollars)Zoetis revenue 2016-2018, by animal type
- Zoetis global revenue from 2016 to 2018, by product category (in million U.S. dollars)Zoetis revenue 2016-2018, by product type
- Revenue distribution
- Distribution of Zoetis' global revenue in 2018, by speciesZoetis revenue distribution in 2018, by species
- Distribution of Zoetis' global revenue in 2018, by countryZoetis revenue distribution in 2018, by country
- Distribution of Zoetis' revenue by animal type in 2018, by countryZoetis revenue share by animal type and country 2018
- Distribution of Zoetis' global revenue in 2018, by product categoryZoetis revenue distribution in 2018, by product category
- Other key data
- Zoetis' net income from 2014 to 2018 (in million U.S. dollars)Zoetis net income 2014-2018
- Zoetis' research and development expenses from 2016 to 2018 (in million U.S. dollars)Zoetis research and development expenses 2016-2018
- Zoetis' earnings per basic share from 2014 to 2018 (in U.S. dollars)Zoetis earnings per basic share from 2014 to 2018
- Zoetis' total assets from 2014 to 2018 (in million U.S. dollars)Zoetis total assets from 2014 to 2018
- Zoetis' total employees from 2013 to 2018Zoetis total employees from 2013 to 2018
- Market size therapy drugs Aurobindo Pharma Limited in India by type FY 2018
- Net debt to equity ratio of Aurobindo Pharma Limited in India 2012-2018
- Net profits of Aurobindo Pharma Limited in India 2012-2018
- Revenue of Aurobindo Pharma Limited in India 2012-2019
- Share of EBITDA margin of Aurobindo Pharma Limited in India 2012-2018
- Share of revenue of Aurobindo Pharma Limited in India FY 2018, by type
- Number of Aurobindo Pharma Limited's ANDAs in India by therapy FY 2018
- Net debt to EBITDA ratio of Aurobindo Pharma Limited in India 2012-2018
- Revenue from ARV formulations of Aurobindo Pharma Limited 2012-2018
- Revenue from U.S. formulations of Aurobindo Pharma Limited 2012-2018
- Share of revenue from growth market formulations of Aurobindo Pharma 2012-2018
- Share of revenue from U.S. formulations of Aurobindo Pharma Limited 2012-2018
- Share of revenue from EU formulations of Aurobindo Pharma Limited 2012-2018
- Revenue from EU formulations of Aurobindo Pharma Limited 2012-2018
- Expenditure on R&D by Aurobindo Pharma Limited 2016-2018 by type
- Daiichi Sankyo's total assets FY 2012-2017
- Diluted EPS for Dr. Reddy's Laboratories Limited 2013-2019
- Dr. Reddy's Laboratories Limited shareholder distribution India 2017-2019
- Daiichi Sankyo's total employees FY 2012-2017
- Lundbeck Annual Report 2018
- Novo Nordisk ANNUAL REPORT 2017
- LEO Pharma A/S Annual Report 2017
- Sobi Anual and sustainability report 2017
- Pharmaceutical industry in Italy
- Pharmaceutical trends in Europe
- Biotechnology Industry in Europe
- Lundbeck Annual Report 2017
- Teva - 2018 Form 10-K
- Boehringer Ingelheim - Annual Report 2018
- Medtronic - 2019 Form 10-K
- Value and Innovation Framework Report 2019
- Pharmaceutical industry in the Netherlands
- Indicatori Farmaceutici
- PAGB Annual Review 2017-2018
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
- Demographics
- Economy
- Education & Science
- Politics & Government
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
You can only download this statistic as a Premium user.
You can only download this statistic as a Premium user.
You can only download this statistic as a Premium user.
As a Premium user you get access to the detailed source references and background information about this statistic.
As a Premium user you get access to background information and details about the release of this statistic.
As soon as this statistic is updated, you will immediately be notified via e-mail.
...and make my research life easier.
You need at least a Premium Account to use this feature.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.